Theriva Biologics Inc. (TOVX)
Theriva Biologics Statistics
Share Statistics
Theriva Biologics has 2.78M shares outstanding. The number of shares has increased by -83.9% in one year.
| Shares Outstanding | 2.78M |
| Shares Change (YoY) | -83.9% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.75M |
| Failed to Deliver (FTD) Shares | 2.32K |
| FTD / Avg. Volume | 3.72% |
Short Selling Information
The latest short interest is 79.02K, so 2.84% of the outstanding shares have been sold short.
| Short Interest | 79.02K |
| Short % of Shares Out | 2.84% |
| Short % of Float | 2.85% |
| Short Ratio (days to cover) | 4.56 |
Valuation Ratios
The PE ratio is -0.09 and the forward PE ratio is -0.23. Theriva Biologics's PEG ratio is 0.
| PE Ratio | -0.09 |
| Forward PE | -0.23 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 0.12 |
| P/FCF Ratio | -0.14 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Theriva Biologics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.15, with a Debt / Equity ratio of 0.08.
| Current Ratio | 2.15 |
| Quick Ratio | 2.15 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | -0.06 |
| Debt / FCF | -0.09 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.28M |
| Employee Count | 20 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -85.14% in the last 52 weeks. The beta is 1.17, so Theriva Biologics's price volatility has been higher than the market average.
| Beta | 1.17 |
| 52-Week Price Change | -85.14% |
| 50-Day Moving Average | 1.31 |
| 200-Day Moving Average | 2.45 |
| Relative Strength Index (RSI) | 58.79 |
| Average Volume (20 Days) | 62.32K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -26.35M |
| Net Income | -25.65M |
| EBITDA | -26.35M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -19.03 |
Balance Sheet
The company has 11.61M in cash and 1.47M in debt, giving a net cash position of 10.14M.
| Cash & Cash Equivalents | 11.61M |
| Total Debt | 1.47M |
| Net Cash | 10.14M |
| Retained Earnings | -334.97M |
| Total Assets | 35.35M |
| Working Capital | 8.7M |
Cash Flow
In the last 12 months, operating cash flow was -16.94M and capital expenditures -1K, giving a free cash flow of -16.94M.
| Operating Cash Flow | -16.94M |
| Capital Expenditures | -1K |
| Free Cash Flow | -16.94M |
| FCF Per Share | -12.56 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TOVX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for TOVX is $6, which is 328.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $6 |
| Price Target Difference | 328.6% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Aug 26, 2024. It was a backward split with a ratio of 1:25.
| Last Split Date | Aug 26, 2024 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -14.67 |
| Piotroski F-Score | 1 |